CHAARTED — Chemohormonal Therapy Versus Androgen Ablation Alone for Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 · 2015 · Prostate Cancer

Design

Randomized androgen-deprivation therapy plus 6 cycles of docetaxel vs androgen-deprivation therapy alone.

Population

Metastatic hormone-sensitive prostate cancer, stratified by high vs low volume of disease.

Primary Endpoint

overall survival (OS)

Key Result

Median OS 57.6 vs 44.0 mo (HR 0.61) overall, with the largest benefit in high-volume disease (49.2 vs 32.2 mo).

Guideline Impact

NCCN category 1 docetaxel intensification for metastatic castration-sensitive prostate cancer